Here's what we'll cover
Here's what we'll cover
Zepbound and Trulicity are both manufactured by Eli Lilly, both involve the incretin system, and both are injectable once weekly medications. That is roughly where the similarities end. These are different molecules, approved a decade apart, for different conditions, with meaningfully different efficacy.
Most people searching this comparison fall into one of two groups: people on Trulicity for diabetes wondering whether Lilly's newer drug is better, or people researching weight loss who have encountered both names. The answer depends entirely on which group you are in.
What Each Drug Is Approved For
Zepbound (tirzepatide, Eli Lilly) is FDA approved for:
- Chronic weight management in adults with obesity or overweight with at least one weight related condition
- Moderate to severe obstructive sleep apnea in adults with obesity
Trulicity (dulaglutide, Eli Lilly) is FDA approved for:
- Type 2 diabetes in adults and pediatric patients aged 10 and older, as an adjunct to diet and exercise
- Reducing the risk of major cardiovascular events in adults with Type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors
Same manufacturer. Completely different approved uses. Trulicity has no weight management indication. Zepbound has no diabetes indication (that belongs to Mounjaro, the same tirzepatide molecule approved for Type 2 diabetes).
| Factor | Zepbound (tirzepatide) | Trulicity (dulaglutide) |
|---|---|---|
| Manufacturer | Eli Lilly | Eli Lilly |
| Drug class | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA initial approval | 2023 (weight management) | 2014 (Type 2 diabetes) |
| Approved for weight loss | Yes | No |
| Approved for Type 2 diabetes | As Mounjaro (separate brand) | Yes |
| Cardiovascular risk reduction | Not yet approved | Yes (REWIND trial, requires Type 2 diabetes) |
| Obstructive sleep apnea | Yes | No |
| Dose range | 2.5 mg to 15 mg weekly | 0.75 mg to 4.5 mg weekly |
The Molecules: One Pathway Versus Two
Dulaglutide (Trulicity) is a GLP-1 receptor agonist only. It activates one incretin pathway, mimicking the gut hormone GLP-1 to slow gastric emptying, reduce appetite, and stimulate insulin secretion when blood sugar is elevated. It was FDA approved in 2014 and has a decade of real world use.
Tirzepatide (Zepbound/Mounjaro) is a dual agonist that activates both the GLP-1 receptor and the GIP receptor (glucose dependent insulinotropic polypeptide). Adding this second pathway appears to be the primary reason tirzepatide produces larger effects on both weight and glucose compared with GLP-1 only drugs.
This is not just a branding difference. It is a fundamentally different pharmacological approach, and the clinical results reflect that.
Efficacy: A Generational Gap
There is no head to head trial of Zepbound against Trulicity specifically. But the evidence from adjacent trials makes the relative performance clear.
In the SURPASS-2 trial, tirzepatide was compared against semaglutide 1 mg (Ozempic dosing) in patients with Type 2 diabetes. Tirzepatide outperformed semaglutide on both A1C and weight loss at all three doses tested. And in the SUSTAIN-7 trial, semaglutide had already outperformed dulaglutide on both measures.
The chain of evidence: tirzepatide beat semaglutide, semaglutide beat dulaglutide. The gap between tirzepatide and dulaglutide is the largest in this sequence.
For weight loss specifically, the SURMOUNT-1 trial showed tirzepatide at its highest dose producing roughly 21% body weight loss over 72 weeks. Trulicity at its highest dose (4.5 mg) in diabetes trials produces weight loss in the range of 3 to 5 kg, a fraction of what tirzepatide achieves. These are fundamentally different magnitudes of effect.
No waiting list. No insurance needed.
Frequently Asked Questions
What is the difference between Zepbound and Trulicity?
Zepbound is a dual GIP and GLP-1 receptor agonist (tirzepatide). Trulicity is a GLP-1 receptor agonist only (dulaglutide). The dual mechanism is the likely reason tirzepatide produces larger effects on both weight and glucose.
Can I use Trulicity for weight loss?
No. Trulicity is approved for Type 2 diabetes and cardiovascular risk reduction in diabetes patients. It is not approved for weight loss.
Is Mounjaro the same as Trulicity?
Mounjaro contains the identical molecule as Zepbound (tirzepatide), but is approved for Type 2 diabetes rather than weight loss. Trulicity contains dulaglutide, an older, less potent GLP-1 agonist.
Is Zepbound more effective than Trulicity?
In the SURPASS-2 trial, tirzepatide (the molecule in Zepbound and Mounjaro) outperformed semaglutide 1 mg, which itself outperformed dulaglutide in prior head to head research. The efficacy gap between tirzepatide and dulaglutide is substantial.
Does Trulicity have fewer side effects than Zepbound?
Trulicity has lower rates of nausea, diarrhea, vomiting, and constipation. For patients who have had tolerability issues with stronger GLP-1 medications, this is a meaningful practical advantage.
Does Zepbound protect your heart?
Trulicity has a cardiovascular indication from the REWIND trial. Zepbound does not yet have a cardiovascular indication, though tirzepatide is being studied in cardiovascular outcome trials.
Dosing: Narrower Range vs Wider Range
| Dosing Detail | Zepbound (tirzepatide) | Trulicity (dulaglutide) |
|---|---|---|
| Starting dose | 2.5 mg weekly | 0.75 mg weekly |
| Escalation schedule | Every 4 weeks in 2.5 mg increments | Increase to 1.5 mg after 4 weeks, then optional 1.5 mg increments every 4 weeks |
| Maintenance dose | 5 mg to 15 mg weekly (physician selected) | 1.5 mg to 4.5 mg weekly |
| Time to maintenance | Minimum 8 weeks, up to 20 weeks at highest dose | 4 weeks minimum, up to 12 weeks at highest dose |
| Available forms | Prefilled pen, KwikPen, vial | Prefilled pen only |
Zepbound's wider range (up to 15 mg) gives physicians substantially more room to titrate. Trulicity reaches therapeutic levels faster because its dose ceiling is lower. Both are once weekly subcutaneous injections administered on the same day each week.
Use Cases: Which Drug Fits Which Situation
You are on Trulicity for diabetes and want tirzepatide. The switch makes sense on efficacy, but Mounjaro (tirzepatide for diabetes), not Zepbound (tirzepatide for weight loss), is the appropriate on label path. Same molecule, same manufacturer, but the diabetes indication gives you a much cleaner insurance route.
You want a weight loss medication and do not have diabetes. Trulicity is not relevant. It has no weight management indication. Zepbound and Wegovy are the on label options.
You have Type 2 diabetes and want the strongest available glucose and weight control. Tirzepatide outperformed semaglutide in SURPASS-2, and semaglutide outperformed dulaglutide in SUSTAIN-7. The chain of evidence puts tirzepatide well ahead. Ask your physician about Mounjaro.
You have cardiovascular disease with Type 2 diabetes. Trulicity has the cardiovascular indication from REWIND. Zepbound does not have a cardiovascular indication yet. If heart protection is a primary goal alongside your diabetes management, Trulicity still has a role that tirzepatide cannot yet fill on label.
You have struggled with GI tolerability. Trulicity's nausea and diarrhea rates are roughly half of Zepbound's. If prior GLP-1 medications caused side effects that led you to stop treatment, Trulicity's gentler profile may keep you on therapy longer, which matters more than peak efficacy you cannot sustain.
You want obstructive sleep apnea treatment alongside weight management. Only Zepbound carries this FDA indication. Trulicity does not.
Side Effects: Tirzepatide Sits Between the Two
Zepbound's GI side effect rates fall between Wegovy (higher) and Trulicity (lower), consistent with tirzepatide's position in potency relative to the other two molecules.
| Side Effect | Zepbound (tirzepatide) | Trulicity (dulaglutide 1.5 mg) |
|---|---|---|
| Nausea | 25 to 29% | 12 to 21% |
| Diarrhea | 19 to 23% | 8 to 12% |
| Vomiting | 8 to 13% | 6 to 12% |
| Constipation | 11 to 17% | 4 to 6% |
| Stomach pain | 9 to 10% | 6 to 9% |
Both carry the same boxed warning about thyroid C cell tumors, pancreatitis, gallbladder disease, kidney injury from dehydration, and hypersensitivity reactions. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Related Comparisons
- Ozempic vs Zepbound: Why You Are Comparing Two Drugs Approved for Different Things
- Wegovy vs Mounjaro: The Comparison That Changes Depending on Which Country You Are In
- Wegovy vs Trulicity: An Older GLP-1 Against a Newer One
Medication guides: Zepbound, Trulicity, Mounjaro, Wegovy
GLP-1.com can help. Compare top GLP-1 providers side by side, explore GLP-1 coupons and savings programs to reduce your monthly cost, and use our resources to go into your next doctor's appointment with better questions and clearer goals. Your health decisions should be driven by evidence and your own priorities. We are here to make sure you have both.
This content is for informational purposes only and is not medical advice. GLP-1.com does not sell or dispense medication. Consult a licensed physician regarding any treatment decision.